Cortex’s CEO to Present at Rodman & Renshaw’s Tenth Annual Healthcare Conference on November 10, 2008

  
    
  
  
    
      Cortex Pharmaceuticals, Inc. (NYSE Alternext US (COR)) President and 
      CEO, Mark A. Varney, Ph.D., will present at Rodman & Renshaw’s 
      Tenth Annual Healthcare Conference taking place November 10 - 12, 
      2008, at the New York Palace Hotel. Dr. Varney will give the Company 
      presentation on Monday, November 10 at 11:10 AM (EST) in the Holmes II 
      Room. Additional information regarding the conference can be found at http://www.rodmanandrenshaw.com/conferences?id=19.
    
    
      Dr. Varney will provide a brief corporate overview as well as an update 
      on the Company’s latest clinical developments, 
      including recently reported positive top-line data from its second Phase 
      IIa study in opioid-induced respiratory depression with the AMPAKINE® 
      compound CX717. CX717 achieved statistical significance (p = 0.005) over 
      placebo on the primary endpoint measure of spontaneous basal respiration 
      without affecting opioid-induced analgesia.
    
    
      To access a live audio webcast or the subsequent archived recording, log 
      on to http://www.wsw.com/webcast/rrshq14/cor. 
      Please connect to the website several minutes prior to the start of the 
      live webcast to ensure adequate time for any software download that may 
      be necessary. An archive of the replay will be available for ninety days 
      at http://www.cortexpharm.com.
    
    
      Cortex Pharmaceuticals, Inc.
    
    
      Cortex, located in Irvine, California, is a neuroscience company focused 
      on novel drug therapies for treating psychiatric disorders, neurological 
      diseases and brain mediated breathing disorders. Cortex is pioneering a 
      class of proprietary pharmaceuticals called AMPAKINE compounds, which 
      act to increase the strength of signals at connections between brain 
      cells. The loss of these connections is thought to be responsible for 
      memory and behavior problems in Alzheimer’s 
      disease. Many psychiatric diseases, including schizophrenia, occur as a 
      result of imbalances in the brain’s 
      neurotransmitter system. These imbalances may be improved by using the 
      AMPAKINE technology. For additional information regarding Cortex, please 
      visit Cortex Pharmaceuticals’ website at http://www.cortexpharm.com.